Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: A pharmacokinetic study

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2472-2484

  Batty, Kevin T ^a,b   Salman, Sam ^c   Moore, Brioni R ^c   Benjamin, John ^d   Lee, Sook Ting ^c   Page Sharp, Madhu ^a   Pitus, Nolene ^d   Ilett, Kenneth F ^c   Mueller, Ivo ^e,f   Hombhanje, Francis W ^g   Siba, Peter ^d   Davis, Timothy M E ^c  

^a CURTIN UNIVERSITY   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^e WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^g Divine Word University   (Papua New Guinea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ PLUS APHTHOQUINE; UNCLASSIFIED DRUG; WATER;

AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALARIA FALCIPARUM; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MILK; NONHUMAN; PAPUA NEW GUINEA; PLASMODIUM VIVAX MALARIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SINGLE DRUG DOSE; STEADY STATE;

ANTIMALARIALS; ARTEMISININS; BIOLOGICAL AVAILABILITY; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HALF-LIFE; HUMANS; MALARIA, FALCIPARUM; MALARIA, VIVAX; MALE; MASS SPECTROMETRY; NAPHTHOQUINONES; PAPUA NEW GUINEA; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

EID: 84860132460     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06250-11     Document Type: Article

References (54)

1. Alin MH, Ashton M, Kihamia CM, Mtey GJ, Bjorkman A. 1996. Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. Br. J. Clin. Pharmacol. 41:587-592. (Pubitemid 26184681)
2. Anderson BJ, Holford NH. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332. (Pubitemid 351738156)
3. Ashley EA, et al. 2007. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop. Med. Int. Health 12:195-200.
4. Ashton M, et al. 1998. Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses. Biopharm. Drug Dispos. 19:245-250. (Pubitemid 28218419)
5. Ashton M, et al. 1998. Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin. Pharmacol. Ther. 63:482-493. (Pubitemid 28214972)
6. Batty KT, et al. 1996. Selective high-performance liquid chromatographic determination of artesunate and alpha-and betadihydroartemisinin in patients with falciparum malaria. J. Chromatogr. B Biomed. Appl. 677:345-350. (Pubitemid 26106005)
7. Benjamin J, et al. 2012. Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a tolerability, safety, and preliminary efficacy study. Antimicrob. Agents Chemother. 56:2465-2471.
8. Beovic B, et al. 1999. Influence of fever on the pharmacokinetics of ciprofloxacin. Int. J. Antimicrob. Agents 11:81-85. (Pubitemid 29067422)
9. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13:143-151.
10. Boudreau EF, et al. 1990. Mefloquine kinetics in cured and recrudescent patients with acute falciparum malaria and in healthy volunteers. Clin. Pharmacol. Ther. 48:399-409. (Pubitemid 20362273)
11. Crevoisier C, Handschin J, Barre J, Roumenov D, Kleinbloesem C. 1997. Food increases the bioavailability of mefloquine. Eur. J. Clin. Pharmacol. 53:135-139. (Pubitemid 27491666)
12. Crowe A, Ilett KF, Karunajeewa HA, Batty KT, Davis TM. 2006. Role of P glycoprotein in absorption of novel antimalarial drugs. Antimicrob. Agents Chemother. 50:3504-3506. (Pubitemid 44527539)
13. Davis TM, et al. 2007. Assessment of the effect of mefloquine on artesunate pharmacokinetics in healthy male volunteers. Antimicrob. Agents Chemother. 51:1099-1101. (Pubitemid 46355304)
14. de Vries PJ, Dien TK. 1996. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 52:818-836. (Pubitemid 26413293)
15. De Vries PJ, et al. 1997. The pharmacokinetics of a single dose of artemisinin in patients with uncomplicated falciparum malaria. Am. J. Trop. Med. Hyg. 56:503-507. (Pubitemid 27230070)
16. Dien TK, et al. 1997. Effect of food intake on pharmacokinetics of oral artemisinin in healthy Vietnamese subjects. Antimicrob. Agents Chemother. 41:1069-1072. (Pubitemid 27194187)
17. Dondorp AM, et al. 2010. Artemisinin resistance: current status and scenarios for containment. Nat. Rev. Microbiol. 8:272-280.
18. Duc DD, et al. 1994. The pharmacokinetics of a single dose of artemisinin in healthy Vietnamese subjects. Am. J. Trop. Med. Hyg. 51:785-790.
19. Edwards G, et al. 1988. Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. Br. J. Clin. Pharmacol. 25:477-485.
20. Ezzet F, Mull R, Karbwang J. 1998. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br. J. Clin. Pharmacol. 46:553-561. (Pubitemid 28522119)
21. Frisk-Holmberg M, Bergqvist Y, Termond E, Domeij-Nyberg B. 1984. The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects. Eur. J. Clin. Pharmacol. 26:521-530. (Pubitemid 14149135)
22. German PI, Aweeka FT. 2008. Clinical pharmacology of artemisininbased combination therapies. Clin. Pharmacokinet. 47:91-102.
23. Gustafsson LL, et al. 1983. Disposition of chloroquine in man after single intravenous and oral doses. Br. J. Clin. Pharmacol. 15:471-479. (Pubitemid 13114651)
24. Hai TN, Hietala SF, Van Huong N, Ashton M. 2008. The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop. 107:145-149.
25. Hassan Alin M, Ashton M, Kihamia CM, Mtey GJ, Bjorkman A. 1996. Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans. R. Soc. Trop. Med. Hyg. 90:61-65. (Pubitemid 26069449)
26. Hien TT, et al. 2011. Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study. Clin. Ther. 33:644-654.
27. Hung TY, et al. 2004. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57:253-262.
28. Johnson TN. 2008. The problems in scaling adult drug doses to children. Arch. Dis. Child. 93:207-211. (Pubitemid 352025489)
29. Jonsson EN, Karlsson MO. 1999. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64. (Pubitemid 29049052)
30. Karunajeewa HA, et al. 2008. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob. Agents Chemother. 52:237-243.
31. Karunajeewa HA, et al. 2008. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 359:2545-2557.
32. Karunajeewa HA, et al. 2010. Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. Antimicrob. Agents Chemother. 54:1186-1192.
33. Kunming Pharmaceutical Corporation. 2006. Instruction for use of compound naphthoquine phosphate tablets. Product information brochure. Kunming Pharmaceutical Corporation, Kunming, Yunnan Province, China.
34. Kurth F, et al. 2010. Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. Lancet Infect. Dis. 10:125-132.
35. Mackowiak PA. 1989. Influence of fever on pharmacokinetics. Rev. Infect. Dis. 11:804-807.
36. Manning L, et al. 2011. Meningeal inflammation increases artemether concentrations in cerebrospinal fluid in Papua New Guinean children treated with intramuscular artemether. Antimicrob. Agents Chemother. 55:5027-5033.
37. Matuszewski BK, Constanzer ML, Chavez-Eng CM. 2003. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 75:3019-3030. (Pubitemid 36830428)
38. Nigerian-German Chemicals Plc. January 2012, accession date. ARCO product information. Nigerian-German Chemicals Plc, Lagos, Nigeria. www.ngcplc.com/arco/index.html.
39. Obua C, et al. 2008. Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. Br. J. Clin. Pharmacol. 65:493-501. (Pubitemid 351365129)
40. Price R, et al. 1999. Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria. Antimicrob. Agents Chemother. 43:341-346. (Pubitemid 29079169)
41. Qu HY, et al. 2010. Single-dose safety, pharmacokinetics, and food effects studies of compound naphthoquine phosphate tablets in healthy volunteers. J. Clin. Pharmacol. 50:1310-1318.
42. Ritschel WA, Kearns GL. 2004. Handbook of basic pharmacokinetics, 6th ed. American Pharmacists Association, Washington DC.
43. Rozet E, Marini RD, Ziemons E, Boulanger B, Hubert P. 2011. Advances in validation, risk and uncertainty assessment of bioanalytical methods. J. Pharm. Biomed. Anal. 55:848-858.
44. Shi B, et al. 2006. Quantitative analysis of artemether and its metabolite dihydroartemisinin in human plasma by LC with tandem mass spectrometry. Chromatographia 64:523-530. (Pubitemid 44914983)
45. Sidhu JS, et al. 1998. Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br. J. Clin. Pharmacol. 45:347-354. (Pubitemid 28138826)
46. Sim IK, Davis TM, Ilett KF. 2005. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob. Agents Chemother. 49:2407-2411. (Pubitemid 40734473)
47. Tarning J, et al. 2008. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob. Agents Chemother. 52:1052-1061. (Pubitemid 351358388)
48. Tarning J, et al. 2005. Pitfalls in estimating piperaquine elimination. Antimicrob. Agents Chemother. 49:5127-5128. (Pubitemid 41778931)
49. Upton RN, Ludbrook GL. 2005. Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of drugs - method development and application to magnesium in sheep. BMC Pharmacol. 5:5.
50. Wang JY, et al. 2004. Naphthoquine phosphate and its combination with artemisinine. Acta Trop. 89:375-381.
51. Welling PG. 1996. Effects of food on drug absorption. Annu. Rev. Nutr. 16:383-415.
52. Wetsteyn JC, De Vries PJ, Oosterhuis B, Van Boxtel CJ. 1995. The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. Br. J. Clin. Pharmacol. 39:696-699.
53. White NJ, Watt G, Bergqvist Y, Njelesani EK. 1987. Parenteral chloroquine for treating falciparum malaria. J. Infect. Dis. 155:192-201. (Pubitemid 17022857)
54. World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed. World Health Organization, Geneva, Switzerland.